Board Member
Xilio Therapeutics, Inc. (XLO)Board Member
Anika Therapeutics, Inc. (ANIK)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Cheryl Blanchard is recorded as CEO and Board Member at Anika Therapeutics, Inc. (ANIK) and Board Member at Xilio Therapeutics, Inc. (XLO). The proxy statement of Anika Therapeutics, Inc. reports total compensation of $4,887,318 for Cheryl Blanchard in fiscal 2025, including a base salary of $750,397. Disclosed compensation is on record for 8 fiscal years. Cheryl Blanchard has spoken on 23 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on November 5, 2025.
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2018-01-01–present
Proxy statement
Start not stated–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2018-01-01–present
Other people whose current roles at this company are on record from its filings.
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | CEO | $750,397 | $4,887,318 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | CEO | $743,943 | $5,103,466 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | CEO | $726,000 | $4,459,800 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | CEO | $695,100 | $5,940,722 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | CEO | $668,400 | $4,202,608 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | CEO | $548,077 | $10,029,434 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | CEO | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | CEO | — | — |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
